UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 41

Sortiert nach

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

Oncotarget, 2016-09, Vol.7 (39), p.64431-64446

2016

Volltextzugriff (PDF)

Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician's perception according to patient comorbidities

International Brazilian journal of urology, 2021-03, Vol.47 (2), p.359-373

2021

Volltextzugriff (PDF)

Identification of the TP53 p.R337H Variant in Tumor Genomic Profiling Should Prompt Consideration of Germline Testing for Li-Fraumeni Syndrome

JCO global oncology, 2021-07, Vol.7 (7), p.1141-1150

2021

Volltextzugriff (PDF)

Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development

Current oncology reports, 2020-07, Vol.22 (7), p.70-70, Article 70

2020

Volltextzugriff (PDF)

Oncology Clinical Trials During the COVID-19 Pandemic

Oncology (Williston Park, N.Y.), 2020-07, Vol.34 (7), p.265-269

2020

Volltextzugriff (PDF)

Cardiovascular and Thromboembolic Events in Patients With Localized Prostate Cancer Receiving Intensified Neoadjuvant Androgen Deprivation: A Systematic Review and Meta-Analysis

Clinical genitourinary cancer, 2024-06, Vol.22 (3), p.102088-102088, Article 102088

2024

Volltextzugriff (PDF)

PD-L1 gene amplification and focality: relationship with protein expression

Journal for immunotherapy of cancer, 2023-02, Vol.11 (2), p.e006311

2023

Volltextzugriff (PDF)

Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis

Translational oncology, 2022-05, Vol.19, p.101383-101383, Article 101383

2022

Volltextzugriff (PDF)

Autoimmune features caused by dengue fever: a case report

The Brazilian journal of infectious diseases, 2012-01, Vol.16 (1), p.92-95

2012

Volltextzugriff (PDF)

Autoimmune features caused by dengue fever: a case report

The Brazilian journal of infectious diseases, 2012-02, Vol.16 (1), p.92-95

2012

Volltextzugriff (PDF)

Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic

Clinical cancer research, 2014-12, Vol.20 (23), p.5956-5963

2014

Volltextzugriff (PDF)

Phase I trials of antitumour agents: fundamental concepts

Ecancermedicalscience, 2015-01, Vol.9, p.501-501

2015

Volltextzugriff (PDF)

HSD3B1 polymorphism in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP): Pharmacodynamics and therapeutic implications

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.140-140

2022

Volltextzugriff (PDF)

Cardiovascular toxicity incidence following immune checkpoint inhibitors in randomized clinical trials: A systematic review and meta-analysis

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.2636-2636

2021

Volltextzugriff (PDF)

MP10-01 OVERVIEW OF 510(K) CLEARED MEDICAL DEVICES AND RECALLS IN URO-ONCOLOGY FROM 2014 THROUGH 2017: IMPLICATIONS FOR SAFETY

The Journal of urology, 2019-04, Vol.201 (Supplement 4)

2019

Volltextzugriff (PDF)

Extreme bipolar androgen therapy with darolutamide and testosterone cypionate in patients with metastatic castration-resistant prostate cancer: ExBAT (LACOG 0620) trial

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS276-TPS276

2023

Volltextzugriff (PDF)

Landscape of cyclin pathway genomic alterations across 7,207 non-prostate genitourinary tumors

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.549-549

2020

Volltextzugriff (PDF)

Cyclin pathway genomic alterations across 5,356 prostate cancers

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.179-179

2020

Volltextzugriff (PDF)

Impact of the biomarker enrichment strategy in drug development

Expert review of molecular diagnostics, 2020-06, Vol.20 (6), p.611-618

2020

Volltextzugriff (PDF)

An appraisal of drug development timelines in the Era of precision oncology

Oncotarget, 2016-08, Vol.7 (33), p.53037-53046

2016

Volltextzugriff (PDF)

Low energy amplitude modulated radiofrequency electromagnetic fields to show antitumor effect in combination with standard treatment or as monotherapy in patients with advanced hepatocellular carcinoma

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.332-332

2021

Volltextzugriff (PDF)

Low energy amplitude modulated radiofrequency electromagnetic fields in combination with standard treatment or as monotherapy to show improvement in quality of life in patients with advanced hepatocellular carcinoma

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.290-290

2021

Volltextzugriff (PDF)

Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective

Journal of medical economics, 2021-01, Vol.24 (1), p.291-298

2021

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(40)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(24)
Life Sciences & Biomedicine
(21)
Oncology
(16)
Humans
(15)
Female
(7)
Male
(7)
Brazil
(6)
Adult
(5)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)
Clinical Trials
(4)
Treatment Outcome
(4)
Urology & Nephrology
(4)
Aged
(3)
Antineoplastic Agents - Therapeutic Use
(3)
Biomarkers
(3)
Drug Development
(3)
Materials Science
(3)
Middle Aged
(3)
Patients
(3)
Retrospective Studies
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician's perception according to patient comorbidities

Identification of the TP53 p.R337H Variant in Tumor Genomic Profiling Should Prompt Consideration of Germline Testing for Li-Fraumeni Syndrome

Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development

Oncology Clinical Trials During the COVID-19 Pandemic

Cardiovascular and Thromboembolic Events in Patients With Localized Prostate Cancer Receiving Intensified Neoadjuvant Androgen Deprivation: A Systematic Review and Meta-Analysis

PD-L1 gene amplification and focality: relationship with protein expression

Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis

Autoimmune features caused by dengue fever: a case report

Autoimmune features caused by dengue fever: a case report

Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic

Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries

Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC)

Phase I trials of antitumour agents: fundamental concepts

HSD3B1 polymorphism in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP): Pharmacodynamics and therapeutic implications

Cardiovascular toxicity incidence following immune checkpoint inhibitors in randomized clinical trials: A systematic review and meta-analysis

MP10-01 OVERVIEW OF 510(K) CLEARED MEDICAL DEVICES AND RECALLS IN URO-ONCOLOGY FROM 2014 THROUGH 2017: IMPLICATIONS FOR SAFETY

Extreme bipolar androgen therapy with darolutamide and testosterone cypionate in patients with metastatic castration-resistant prostate cancer: ExBAT (LACOG 0620) trial

Landscape of cyclin pathway genomic alterations across 7,207 non-prostate genitourinary tumors

Cyclin pathway genomic alterations across 5,356 prostate cancers

Impact of the biomarker enrichment strategy in drug development

An appraisal of drug development timelines in the Era of precision oncology

Low energy amplitude modulated radiofrequency electromagnetic fields to show antitumor effect in combination with standard treatment or as monotherapy in patients with advanced hepatocellular carcinoma

Low energy amplitude modulated radiofrequency electromagnetic fields in combination with standard treatment or as monotherapy to show improvement in quality of life in patients with advanced hepatocellular carcinoma

Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective

Suchergebnisse filtern